Philadelphia, PA– Olfactory Biosciences Corp.’s (OLFC ) Chief Scientist Dr. V. Ruth Pinney and developer of NOXO Autism Balm(TM) said that what makes NOXO’s Autism Balm(TM) unique is that it, "Is a simple, but powerful way to ‘tone down’ an autistic child’s overwhelming senses and sensory perceptions. The Autism Balm
WORKS and works well with most children that have Autism Spectrum Disorders (ASD). It is successful because it targets sensitivities naturally, changing
the child's perception to sensory inputs in a direct, safe way!"
Dr. Pinney has invented an inexpensive NOXO Autism Balm™that has proven to bring tranquility to the family and significantly reduce self-stimulating behaviors in autistic children.
extracts to see if she could change the brain’s perception to sensory stimuli including noxious and foul odors.
Wayne Barte, a project manager at the Department of Justice Office of Law Enforcement and Technology Commercialization (OLETC), heard about Pinney’s work just in time for one of the largest cleanup efforts in history. “Right after September 11, we were challenged with what we could do to help first responders who were incurring all kinds of unique sensory inputs while losing focus on the job at hand,” said Barte. He arranged for some of Pinney’s samples to be transported to Ground Zero by humanitarian aid #rights. Two days later, he called back asking for everything she had and to start manufacturing large quantities.All of Dr. Pinney’s work focused on the olfactory receptors and the combination that would target a specific action such as a mood change, but until 2004 targeting
the right receptor was a difficult job.
Then, in 2004, Richard Axel and Linda Buck won the NOBEL Prize in Medicine. They provided the basis for our current understanding receptors and this research brought to light that we have highly specific specialized odorant receptors in the olfactory system that receive only specific odorants.With this groundbreaking understanding and many years of experience with scents, Dr. Pinney was able to create combinations of these scents that work with the olfactory receptors in a natural process of eliciting specific reactions from the brain.
Using this information and Dr. Pinney’s experience, she was able to design formulas and create the current NOXO Autism Balm™.NOXO Autism Balm(TM) is similar to a lip balm but is applied just below the nostrils on the upper lip, allowing the natural formula to be inhaled and take effect. NOXO’s solution is safe, easy to apply and non-invasive. It works on the body’s natural processes and responses. It works very well on its own or with other Autism Spectrum therapies as an adjunct. Autism Aid will also assist in supporting the child in eating a variety of nutritious foods.
Dr. Pinney has been able to work with the autistic individual’s brain chemoreception pathways; thus changing the reactions to the specific sensory perceptions.
About Olfactory Biosciences Corp Image: http://www.accesswire.com/images/594/aid.jpg(http://www.noxoinfo.com/investor)
Olfactory Biosciences Corp.’s NOXO division is focused to develop a variety of products targeting Olfactory Receptors for the desired effect. These alternative medicine wellness products may modify behavior or provide relief to common behavior challenges such as anxiety, smoking or weight control, as examples.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements by the Company, statements regarding the NOXO product line, optimism related to the business, expanding ales and other statements in this press release are forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates and projections about the Company's business. Words such as expects, anticipates, intends, plans, believes, sees, estimates and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve certain risks and uncertainties that are difficult to predict. Actual results could vary materially from the description
contained herein due to many factors including continued market acceptance of the Company's products or the need to raise additional capital. In addition, actual results could vary materially based on changes or slower growth in the indoor garden market; the potential inability to realize expected benefits and synergies; domestic and international business and economic conditions; changes in customer demand or ordering patterns; changes in the competitive environment including pricing pressures or technological changes; technological advances; shortages of manufacturing capacity; future production variables impacting excess inventory and other risk factors listed from time to time in the Company’s Securities and Exchange Commission (SEC) filings under "risk factors" and elsewhere. The forward-looking statements contained in this press release speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this press release.
Richard Stevenson, President
Olfactory Biosciences Corp.
333 E. Lancaster Ave. Suite 317
Wynnewood, PA 19096, USA
Source: Olfactory Biosciences Corp.
- Autism Spectrum Disorders